Having already set out expectations earlier this year that its generics business would grow by 20% in 2023, Hikma has now gone even further by raising its annual guidance to nearly 30% growth for the generics segment.
The prediction follows a tough 2022 that saw an 18% turnover decline in Hikma’s generics business, offset by growth in...








